Tagged with R

AstraZeneca Poland You have been quite recently appointed at the head of the Polish affiliate of AstraZeneca. With which personal ambitions did you come and what was the mission you were given when you took office? I would not say that I have been given a mission, but that I have been…

Ipsen Brazil In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of the newer international companies to Brazil, and you have been here since ground zero in 2007. What prompted that initial…

GSK Brazil You’ve made some bold moves in your career – from the head of vaccines in Latin America, followed by stints in Colombia, Puerto Rico, and finally Brazil. What brought you along that trajectory, and what have been some of the most important milestones since your arrival here in 2008? I…

Farma De Colombia Having just recently celebrated its 50th anniversary in Colombia, how would you describe Farma de Colombia’s unique business model and what have been its keys to its success? We are a brand company. We build marks and brands. While we do sell to the government, our main strength lies in…

Farmindustria & Laboratorio Volta As the CEO of Farmindustria since 1998, what would you say has been your recipe for the impressive success that the company has experienced, considering that Farmindustria represents 35% of all contract manufacturing activities in Chile? Our strongest key to success has certainly been the team that work’s here. Manufacturing…

Meizler Biopharma There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re second generation, of course! I am an architect by training. Before entering the pharmaceutical industry I owned an engineering and…

Merck Chile What have been Merck’s major milestones and achievements for its pharmaceutical division since you took the reins? I have been managing the Pharma division of Merck since 2006 and the biggest milestone since then has definitely been the acquisition of Serono. In Chile Serono was previously represented by a local…

Novo Nordisk Brazil Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other “rich-country” diseases, there is a tendency for its sudden prevalence to result in less-than-adequate treatment profiles. What have you observed here in Brazil? The…

Shire Brazil We asked Mr. Santos regarding his recommendations to help the government innovate, compete, and grow in the pharmaceutical industry here in Brazil on the Human Genetic Therapies side. Is there a different approach required in the specific area of HGT? For HGT, one very important element is the basic regulatory…

Romanian Association of International Drug Manufacturers (ARPIM) While, today, you are in charge of voicing the concerns of the innovators in the country, let us first take a step back and see what attracted these companies to Romania in the first place. Can you tell our readers more about the key factors of attraction in that sense?…

Quintiles Brazil Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that time, and what does Brazil represent for Quintiles? Brazil is a top 3 priority right now for Quintiles. The first…

IMS Health Brazil We know the raw data already in the Brazilian market and the number changes since our last visit in 2007 – but how would you interpret these changes into a coherent story explaining the evolution since that time in the country’s pharmaceutical history? The one major factor influencing country growth…